EP0470569A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Intravascular embolizing agent containing angiogenesis inhibiting substance
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1991-08-06
•
Granted: —
•
Expires: 2011-08-06
Abstract
Abstract The present invention relates to an intravascular embolizing agent containing an angiogenesis-inhibiting substance and an intravascular embolizing substance. The agent strengthens the antitumor effect of an angiogenesis-inhibiting substance and serves to reduce the dose and undesirable side effects. And use of the agent in concert with an anti-neoplastic agent brings about further strong and long-lasting antitumor effects.
Inventors
- 👤 Hiroaki Okada
- 👤 Shigeru Kamei
- 👤 Toshio Yoshioka
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-26 10:08
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/74; A61K31/765; A61K38/00; A61K38/16; A61K38/17; A61K38/38; A61K38/39; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1641; A61K9/1647; A61K9/1658; A61P; A61P35/00; A61P9/00; A61P9/14
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
13 words
An intravascular embolizing agent containing an angiogenesis-inhibiting substance and an intravascular embolizing substance.
Claim 2
Dependent Claim
13 words
An intravascular embolizing agent containing an angiogenesis-inhibiting substance and an intravascular embolizing substance.
Claim 3
Dependent Claim
22 words
An intravascular embolizing agent as claimed in Claim 1 being in the state of an oil solution, an emulsion or a suspension.
Claim 4
Dependent Claim
28 words
An intravascular embolizing agent as claimed in Claim 1 being in the state of an emulsion or suspension containing granules whose size ranges from 10 to 1000 am.
Claim 5
Dependent Claim
17 words
An intravascular embolizing agent as claimed in Claim 1 wherein the angiogenesis-inhibiting substance is a fumagillol derivative.
Claim 6
Dependent Claim
15 words
An intravascular embolizing agent as claimed in Claim 1 wherein the angiogenesis-inhibiting substance is 6-O-(N-chloroacetylcarbamoyl)fumagillol.
Claim 7
Dependent Claim
16 words
An intravascular embolizing agent as claimed in Claim 1 wherein the angiogenesis-inhibiting substance is 6a-(N'-chloroacetylureido)-6-desoxy fumagillol.
Claim 8
Dependent Claim
17 words
An intravascular embolizing agent as claimed in Claim 1 wherein the angiogenesis-inhibiting substance is 4-(N'-chloroacetyluredlo)-2-(1,2-epoxy-1,5-dlmethyl-4-hexenyl)-1-(1,3-dihydrobenzo[c]thiophene-2- ylio)methyl-3-methoxycyclohexanol chloride.
Claim 9
Dependent Claim
21 words
An intravascular embolizing agent as claimed in Claim 1 characterized by having the angiogenesis-inhibiting substance included in the intravascular embolizing substance.
Claim 10
Dependent Claim
22 words
An intravascular embolizing agent as claimed in Claim 1 characterized by that the angiogenesis-inhibiting substance is adsorbed on the intravascular embolizing substance.
Claim 11
Dependent Claim
43 words
An intravascular embolizing agent as claimed in Claim 1 wherein the intravascular embolizing substance is an oil, a metal, an insoluble salt of metal, a ceramic, wax, activated carbon, polypeptide, polysaccharide, hydroxycarboxylic acid polymer, polyamino acid, polyaldehyde, polyvinyl polymer or maleic anhydride polymer.
Claim 12
Dependent Claim
26 words
An intravascular embolizing agent as claimed in Claim 1 wherein the intravascular embolizing substance is a polymer which gradually dissolves or decomposes in a living body.
Claim 13
Dependent Claim
26 words
An intravascular embolizing agent as claimed in Claim 1 wherein the intravascular embolizing substance is gelatin, albumin, collagen, starch hyaluronic acid or lactic acid-glycolic acid copolymer.
Claim 14
Dependent Claim
45 words
An intravascular embolizing agent as claimed in Claim 1 wherein the intravascular embolizing substance is a lactic acid-glycolic acid copolymer whose molar ratio of lactic acid and glycolic acid is in the range of 100/1 to 30/70 and molecular weight ranges from 1,000 to 100,000.
Claim 15
Dependent Claim
28 words
An intravascular embolizing agent as claimed in Claim 1 wherein the angiogenesis-inhibiting substance is a fumagillol derivative and the intravascular embolizing substance is a lactic acid-glycolic acid copolymer.
Claim 16
Dependent Claim
27 words
An intravascular embolizing agent as claimed in Claim 1 wherein the angiogenesis-inhibiting substance is 6-O-(N-chloroacetylcarbamoyl)fumagillol and the intravascular embolizing substance is a lactic acid- glycolic acid copolymer.
Claim 17
Dependent Claim
27 words
An intravascular embolizing agent as claimed in Claim 1 wherein the angiogenesis-inhibiting substance is 6a-(N'-chloroacetylureido)-6-desoxy fumagillol and the intravascular embolizing substance is a lactic acid-glycolic acid copolymer.
Claim 18
Dependent Claim
28 words
An intravascular embolizing agent as claimed in Claim 1 wherein the angiogenesis-inhibiting substance is 4-(N'-chloroacetyluredlo)-2-(1,2-epoxy-1,5-dlmethyl-4-hexenyl)-1-(1,3-dihydrobenzo[c]thiophene-2- ylio)methyl-3-methoxycyclohexanol chloride and the intravascular embolizing substance is lactic acid- glycolic acid copolymer.
Claim 19
Dependent Claim
18 words
An intravascular embolizing agent as claimed in Claim 1 characterized by the agent further contains an anti-neoplastic agent.
Claim 20
Dependent Claim
20 words
A pharmaceutically acceptable composition which comprises an intravascular embolizing agent as claimed in claim 1 and a pharmaceutically acceptable carrier.
Claim 21
Dependent Claim
23 words
Use of an intravascular embolizing agent as claimed in Claim 1 for the preparation of a pharmaceutically acceptable composition for treatment of cancer.
References Cited (Backward Citations)
EP0325199A2
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.